Upcoming Events More events are coming soon. Presentations February 24, 2026 Fourth Quarter and Year End 2025 Earnings Presentation 1.4 MB October 30, 2025 Third Quarter 2025 Earnings Presentation 711.3 KB August 5, 2025 Second Quarter 2025 Earnings Presentation 1.1 MB May 7, 2025 First Quarter 2025 Earnings Presentation 1 MB February 28, 2025 Fourth Quarter and Year End 2024 Earnings Presentation 1.3 MB February 18, 2023 Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells 1.3 MB February 18, 2023 24-Month Safety Results From the OAKS and DERBY Trials With Further Characterization of Exudative Age-Related Macular Degeneration 2.4 MB February 17, 2023 Apellis SYFOVRE FDA Approval Conference Call Presentation 840.9 KB November 3, 2022 Safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the OAKS and DERBY phase 3 trials 910.1 KB November 3, 2022 Efficacy of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the phase 3 OAKS and DERBY trials 1.9 MB Past Events More events are coming soon.
February 18, 2023 Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells 1.3 MB
Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells 1.3 MB
February 18, 2023 24-Month Safety Results From the OAKS and DERBY Trials With Further Characterization of Exudative Age-Related Macular Degeneration 2.4 MB
24-Month Safety Results From the OAKS and DERBY Trials With Further Characterization of Exudative Age-Related Macular Degeneration 2.4 MB
November 3, 2022 Safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the OAKS and DERBY phase 3 trials 910.1 KB
Safety of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the OAKS and DERBY phase 3 trials 910.1 KB
November 3, 2022 Efficacy of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the phase 3 OAKS and DERBY trials 1.9 MB
Efficacy of intravitreal pegcetacoplan in geographic atrophy: 24-month results from the phase 3 OAKS and DERBY trials 1.9 MB